Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Roche 1H Results | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Roche 1H Results

Diagnostics Division sales grew 49% due to high demand for COVID-19 tests and strong momentum in routine testing.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Roche
1H Revenue: 30.7 billion CHF (+5%)
Net Earnings: 8.2 billion CHF (-3%)
Comments: Pharmaceutical Division sales were 21.7 billion CHF down 3. While sales in the first quarter were still strongly affected by COVID-19 (-9%), the second quarter showed signs of recovery in some regions (+4%). The ongoing impact from biosimilars, particularly in the U.S., resulted in a sales decrease of CHF 2.8 billion, however newly launched medicines (+30%) helped offset continued impact from biosimilars. In the first six months, new medicines generated sales of over CHF 11 billion, contributing more than 50% to the division’s total sales.

Ocrevus sales were 2.4 billion CHF, up 23%. Perjeta sales were up 5% to nearly 2.0 billion CHF. Avastin sales were down 40% to 1.6 billion CHF. Actemra/RoActemra sales were up 17% to 1.6 billion CHF. Tecentriq sales were up 29% to 1.6 billion CHF. Herceptin sales were down 35% to 1.4 billion CHF. Hemlibra sales were up 45% to 1.4 billion CHF. MabThera/Rituxan sales were down 41% to 1.4 billion CHF. Kadcyla sales were up 19% to 959 billion CHF.

COVID-19: Additional positive study results for antibody combination Ronapreve (co-developed with Regeneron) and AT-527 (co-developed with Atea); Japan becomes first country to approve Ronapreve for the treatment of mild to moderate COVID-19; FDA Emergency Use Authorization for Actemra/RoActemra.

Diagnostics Division sales grew 49% due to high demand for COVID-19 tests and strong momentum in routine testing. In April, Roche acquired the U.S. company GenMark Diagnostics for $1.9 billion. GenMark’s technology detects a wide range of pathogens from a single patient sample, expanding Roche’s molecular lab portfolio.

Read Contract Pharma’s Top Companies Report on Roche.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters